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Background
A steady increase of product titers and the correspond-
ing change in impurity composition represent a chal-
lenge for development and optimization of antibody
production processes [1,2]. Concentration and composi-
tion of impurities like host cell proteins (HCP) are criti-
cal for efficient process development. These impurities
show significant variations, which primarily depend on
cell culture conditions. They have a strong influence on
the downstream processing (DSP) and costs [2]. It is
already shown that not optimized changes of parameters
in USP can change the impurity profile by a factor of 7
[3]. The resulting “bottleneck” in DSP requires new
optimization, technology and development approaches.
These include the optimization and adaptation of exist-
ing unit operations respective to the new separation
task, the assessment of alternative separation technolo-
gies and the search for new methods in process develop-
ment [2].
Material and Methods
By changing cell culture media compositions according
to DoE screening designs, influences of media compo-
nents on the HCP concentration and composition are
identified. A media optimization is carried out regarding
not only high product titers and cell growth but also
HCP concentration and composition. By these experi-
ments, different fermentation broths are produced con-
taining different concentrations and compositions of
HCP. These broths are used in subsequent development
of ATPE and precipitation. A DoE based screening is
carried out to identify the influence of following para-
meters: system composition, NaCl, cell number, viability,
pH, product concentration, precipitant concentration,
temperature, precipitation environment.
Results
ATPE can be used as cell harvest method. It separates
more than 95 % of cells from the broth. Almost 100 %
of the antibody can be transferred in the top phase. The
product is concentrated within the target phase at
reduced volumes. At the same time, a first purification
step is carried out removing HCP, DNA and media
components. A subsequent precipitation removes the
majority of remaining HCP and other impurities. The
integration of ATP and precipitation can result into a
significant reduction of costs and efforts. An optimiza-
tion of the overall manufacturing process can be
advanced by regarding process depending impurities
resulting from the fermentation process. The optimiza-
tion of USP towards relatively high product titers as
well as an impurity spectrum which is easy to separate
from the product can improve the manufacturing pro-
cess concerning the total process costs.
Conclusions
A combination of an integration of upstream and down-
stream processing regarding process depending impuri-
ties as well as an establishment and integration of
alternative separation mechanisms can present an inter-
esting solution to purify high concentrated antibodies.
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